B类I型清道夫受体的高表达与结肠癌患者预后的相关性

doi:10.6040/j.issn.1671-7554.0.2017.167

摘要/Abstract

摘要： 目的分析B类I型清道夫受体(SR-BI)的表达与结肠癌患者各临床病理变量之间的关系,并探讨SR-BI的表达状态与患者的预后关系,以期寻找新的结肠癌预后指标和潜在的治疗靶点。方法采用免疫组织化学染色方法对购自上海芯超生物科技有限公司的含90例结肠癌组织和相对应的癌旁组织的芯片进行SR-BI表达的检测,并分析其与结肠癌的发生发展、临床病理特征及患者预后的关系。结果 SR-BI在78.9%的结肠癌组织比相对应的癌旁组织表达高(P<0.001),SR-BI的表达水平与临床病理特征无关。在结肠癌组织中,SR-BI低表达的患者比SR-BI高表达的患者总体生存率(OS)缩短(P=0.042)。Cox回归多因素分析提示SR-BI的高表达是影响预后的独立有利因素(P=0.039)。结论 SR-BI表达水平越低,结肠癌患者预后越差。结肠癌组织中SR-BI的表达水平是结肠癌患者的独立预后因素。

关键词: B类I型清道夫受体, 预后, 结肠癌, 免疫组织化学

Abstract: Objective To explore the association between the expression of scavenger receptor class B type I(SR-BI)and the clinicopathological variables, and to determine whether SR-BI expression was an independent prognostic factor and a potential therapeutic target for colon cancer. Methods A well-documented tissue microarray of 90 patients with colon cancer was purchased from Shanghai Outdo Biotech Co., Ltd. The SR-BI expression in the cancer tissues and para-cancerous tissues were detected with immunohistochemical method. The association between SR-BI expression and the clinicopathological variables, and patients outcome was analyzed. Results In 78.9% of the cases, SR-BI expression was higher in the cancer tissues than in the adjacent non-tumor tissues(P<0.001). The expression of SR-BI in colon cancer tissues had no significant statistical association with the clinicopathological variables. Patients with low SR-BI expression in colon cancer tissues had a shorter overall survival(OS)than those with high SR-BI expression(P=0.042). The multivariate analysis confirmed that high SR-BI expression was an independent favorable prognostic factor for OS(P=0.039). Conclusion Low SR-BI expression is associated with unfavorable prognosis of colon cancer. SR-BI is an independent prognostic factor of colon cancer.

Key words: Colon cancer, Prognosis, Scavenger receptor class B type I, Immunohistochemistry

中图分类号:

R735.3

刘惠苓,王兴文,冯少滨,冯虹,韩俊庆. B类I型清道夫受体的高表达与结肠癌患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(10): 84-89.

LIU Huiling, WANG Xingwen, FENG Shaobin, FENG Hong, HAN Junqing. Association between high expression of scavenger receptor class B type I and the prognosis of colon cancer[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 84-89.

参考文献

[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2):115-132.
[2] Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk [J]. Nutr Clin Pract, 2012, 27(5): 613-623.
[3] Barone M, Lofano K, De Tullio N, et al. Dietary, endocrine and metabolic factors in the development of colorectal cancer [J]. J Gastrointest Cancer, 2012, 43(1): 13-19.
[4] Ruder EH, Thiebaut AC, Thompson FE, et al. Adolescent and mid-life diet: risk of colorectal cancer in the NIH-AARP diet and health study [J]. Am J Clin Nutr, 2011, 94(6):1607-1619.
[5] Liao F, He W, Xia L, et al. A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C [J]. Onco Targets Ther, 2015, 8: 3135-3142. doi: 10.2147/OTT.S90479.
[6] Shen WJ, Hu J, Salman Azhar, et al. Scavenger receptor class B type I(SR-BI): a versatile receptor with multiple functions and actions [J]. Metabolism, 2014, 63(7): 875-886.
[7] Pelton K, Freeman MR, Solomon KR. Cholesterol and prostate cancer [J]. Curr Opin Pharmacol, 2012, 12(6): 751-759.
[8] 李文燕, 刘洪涛, 王瑞芝. B 类Ⅰ型清道夫受体SR-BI表达上调剂的研究进展[J]. 沈阳药科大学学报, 2016, 33(6): 507-511.
[9] Danilo C, Gutierrez-Pajares JL, Frank PG, et al. Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development [J]. Breast Cancer Res, 2013, 15(5): R87.
[10] Zheng Y, Liu Y, Zhang Z, et al. Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by high-density lipoprotein-mimetic nanoparticles [J]. Theranostics, 2013, 3(7):477-486.
[11] Muntoni S, Atzori L, Mereu R, et al. Serum lipoproteins and cancer [J]. Nutr Metab Cardiovasc Dis, 2009, 19(3): 218-225.
[12] Jacobs EJ, Stevens VL, Gapstur SM, et al. Plasma total, LDL, and high-density lipoproteincholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort [J]. Cancer Causes Control, 2012, 23(8): 1289-1296.
[13] Cruz P, Mo H, Lacko A, et al. The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics[J]. Front Pharmacol, 2013, 4(119): 3389-3396.
[14] Huang LZ, Gao JL, Zhang Y, et al. Apolipoprotein M: research progress, regulation and metabolic functions [J]. Mol Med Rep, 2015, 12(2): 1617-1624.
[15] Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies [J]. Cancer Causes Control, 2015, 26(2): 257-268.
[16] Davis Yadley AH, Lipka S, Pan Q, et al. Ethnic disparities in the risk of colorectal adenomas associated with lipid levels: a retrospective multiethnic study [J]. J Gastrointest Cancer, 2015, 46(1): 29-35.
[17] Zhang X, Zhao XW, Wang Y, et al. Lipid levels in serum and cancerous tissues of colorectal cancer patients [J]. World J Gastroenterol, 2014, 20(26): 8646-8652.
[18] Borgquist S, Butt T, Melander O, et al. Apolipoproteins, lipids and risk of cancer[J]. Int J Cancer, 2016, 138(11): 2648-2656.
[19] Chandler PD, Song Y, Ridker PM, et al. Lipid biomarkers and long-term risk of cancer in the Womens Health Study [J]. Am J Clin Nutr, 2016, 103(6): 1397-1407.
[20] Coppola JA, Shrubsole MJ, Murff HJ, et al. Plasma lipid levels and colorectal adenoma risk [J]. Cancer Causes Control, 2015, 26(4):635-643.
[21] Wang Y, Wang ZQ, Li YH, et al. Predictive value of chemotherapy-related high-density lipoprotein cholesterol(HDL)elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases [J]. Oncotarget, 2016, 7(35):57290-57300.
[22] 李传凤,李军,白鹏,等.结直肠腺瘤与患者血脂代谢水平[J]. 北京大学学报(医学版),2011,43(3):432-435. LI Chuanfeng, LI Jun, BAI Peng, et al. Characteristic analysis of plasma lipid metabolism level in patients withcolorectal adenoma[J]. Journal of Peking University(Health Science), 2011, 43(3): 432-435.
[23] 申光哲, 金头峰. 结直肠癌与代谢综合征的相关性[J]. 延边大学医学学报, 2015, 38(1): 25-27.
[24] Cruz PM, Mo H, McConathy WJ, et al. The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics [J]. Front Pharmacol, 2013, 4: 119. doi: 10.3389/fphar.2013.00119.
[25] Su F, Grijalva V, Navab K, et al. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer [J]. Mol Cancer Ther, 2012, 11(6): 1311-1319.

相关文章 15

[1]	黄方康瑞吴春林. VEGFC、NF-κBp65及Survivin在鼻咽癌中的表达及临床意义[J]. 山东大学学报(医学版), 2209, 47(6): 83-.
[2]	栗英林,宋道庆,徐忠华. 应用生物信息学方法分析肾透明细胞癌中FKBP11的表达[J]. 山东大学学报 (医学版), 2020, 1(9): 45-51.
[3]	史爽,李娟,米琦,王允山,杜鲁涛,王传新. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报 (医学版), 2020, 1(7): 47-52.
[4]	路璐,孙志钢,张楠. 继发性嗜血细胞综合征1例[J]. 山东大学学报 (医学版), 2020, 1(7): 122-124.
[5]	李星凯,刘战业,姜运峰,李军. 原发性中央型和周围型肺鳞癌临床病理学及预后差异[J]. 山东大学学报（医学版）, 2017, 55(9): 73-78.
[6]	聂思月,王震,孙靖宇,刘杰,李娟,魏小娟,路春晓,吕兴龑,王淑云,孙玉萍. ANGPTL5在人胃癌组织中的表达及临床意义[J]. 山东大学学报（医学版）, 2017, 55(8): 61-65.
[7]	宗帅,肖东杰,刘华,郏雁飞,马晓丽,李焕杰,黎娉,郑燕,汪运山. CSN5在胃癌中的表达及与患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(7): 12-16.
[8]	孙启晶,陈方方,李春晓,张才擎. PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值[J]. 山东大学学报（医学版）, 2017, 55(4): 55-59.
[9]	王永强,张维全,孙启峰,董晓鹏,彭传亮,张媛,赵小刚. 细胞角蛋白14基因在非小细胞肺癌中的表达与意义[J]. 山东大学学报（医学版）, 2017, 55(3): 83-87.
[10]	董尧,宋亚林,田涛,高建国. 确诊8年未经治疗却无明显进展的阴茎恶性黑色素瘤1例报道[J]. 山东大学学报（医学版）, 2017, 55(3): 125-126.
[11]	林家香,郭子嘉,苏鹏,王晓,郭雅欣,吴晓娟,相磊,周志强, 王妍,崔秀杰,潘爱凤,郭成浩. 致癌蛋白CIP2A在乳腺导管上皮恶变中的作用及预测浸润性导管癌患者预后的能力[J]. 山东大学学报（医学版）, 2017, 55(3): 100-106.
[12]	周兰兰,潘学谊,郭煜. 48例急性混合细胞表型白血病患者的临床特征及预后[J]. 山东大学学报（医学版）, 2017, 55(2): 79-83.
[13]	张希英,翟春颜,李劲松,韩博. 中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系[J]. 山东大学学报（医学版）, 2017, 55(2): 84-91.
[14]	王贲士, 单军奇,侯庆生,公为鹏,朱振宇,郭洪亮. CD11b⁺/CD66b^-表型髓系细胞在结肠癌进展和肝转移中的作用[J]. 山东大学学报（医学版）, 2017, 55(10): 41-45.
[15]	李晓宁,崔连群. 急性心肌梗死合并多支血管病变患者非梗死相关动脉处理的时机[J]. 山东大学学报（医学版）, 2016, 54(8): 50-54.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed